Open Outbreak

Chikungunya

Also known as: CHIKV, chikungunya virus disease, chikungunya fever

Chikungunya is a viral disease spread mainly by Aedes mosquitoes, especially Aedes aegypti and Aedes albopictus. People usually get it after a mosquito bite, not from casual contact with an infected person. The illness often starts suddenly with fever and marked joint pain. Headache, muscle pain, fatigue, nausea, rash, and joint swelling can also happen. For many people the worst part is the joint pain, which can be very limiting and may last for months or even years in some cases. Severe illness and death are uncommon, but WHO notes they can occur, especially in infants, older adults, and people with other health problems. The sources retrieved for this page do not establish a single accepted reproduction number, so that remains unknown here. Treatment is mainly supportive: rest, fluids, and medicines to ease pain and fever. The sources retrieved mention vaccine research and development, but they do not clearly establish current global vaccine availability, so vaccine status is listed as unknown in this page. WHO reported renewed global spread in 2025, including outbreaks in places that had not seen substantial recent transmission.

Key facts

TransmissionPrimarily through bites of infected Aedes mosquitoes, especially Aedes aegypti and Aedes albopictus; infected travelers can introduce the virus to new areas where these mosquitoes are present.
IncubationUsually about 4 to 8 days after an infected mosquito bite.
Case fatalityOverall fatality appears low; WHO reported 155 deaths among 445271 suspected and confirmed cases globally from 2025-01-01 to 2025-09-30, but severe and fatal disease can occur, especially in vulnerable groups.
Reproduction numberunknown
Vaccineunknown from the sources retrieved; vaccine candidates are discussed in review literature, but current availability is not clearly established in these sources.
TreatmentNo specific cure established in the sources retrieved; treatment is supportive and focused on relieving symptoms such as pain and fever.
ReservoirHuman-mosquito-human transmission is important in outbreaks; older review literature also describes animal cycles in Africa.
Endemic regionsAfrica, Asia, the Americas, and islands of the Indian Ocean; WHO reported current or previous autochthonous transmission in 119 countries and territories by 2024.

Transmission

Chikungunya spreads mainly through the bite of infected Aedes mosquitoes. WHO and review articles identify Aedes aegypti as the main vector and Aedes albopictus as another important one. These mosquitoes bite during the day as well as around dawn and dusk. Outbreaks can start when a traveler carrying the virus arrives in a place where these mosquitoes are established and local people have little immunity. WHO’s 2025 global update says this is a continuing risk in previously unaffected areas, especially where vector surveillance and control are weak. The sources retrieved for this page do not provide a firm, widely accepted reproduction number for chikungunya, so that figure is best treated as unknown here. The usual incubation period reported in the overview source is about 4 to 8 days after the bite of an infected mosquito.

Symptoms and severity

The usual illness begins suddenly, often with fever and strong joint pain. WHO and review articles also list muscle pain, headache, nausea, fatigue, rash, and joint swelling. The joint pain can be severe enough to limit walking and daily tasks. Many people improve within about a week, but some continue to have pain or stiffness for months or even years. That long tail of symptoms is one reason outbreaks can burden health services even when deaths remain uncommon. Severe disease is not the norm, but it does happen. WHO’s 2025 update says overall fatality is low, while also warning that severe illness and death can occur, especially in infants, older adults, and people with pre-existing conditions. In 2025, WHO reported 155 deaths among 445271 suspected and confirmed cases globally between 2025-01-01 and 2025-09-30.

Treatment and vaccines

Care is mainly supportive. WHO outbreak notices say there is no cure and that treatment focuses on relieving symptoms. In plain terms, that means rest, fluids, and medicines used to reduce pain and fever, while watching closely for patients who may be at higher risk of complications. Early detection and timely access to medical care matter, because WHO notes that prompt care can help reduce complications and deaths. For vaccines, the sources retrieved for this page are incomplete. Older review literature discusses vaccine prospects and active development, showing that vaccination has long been a research goal. However, the documents returned in this session do not clearly state the present global vaccine status, so this page lists vaccine status as unknown rather than guessing. That is a limitation of the source set, not a claim that vaccine work does not exist.

Where it occurs

Chikungunya is no longer limited to a small set of tropical locations. WHO’s 2025 global situation report says current or previous local transmission had been reported from 119 countries and territories by the end of 2024. The disease mostly occurs in Africa, Asia, the Americas, and Indian Ocean islands, but local outbreaks have also happened in parts of Europe where Aedes albopictus is established. WHO notices from France and Italy show how summer transmission can happen outside the traditional tropical range when the vector is present. WHO also warns that 27 countries and territories had competent Aedes aegypti populations but had not yet reported local transmission as of 2024, meaning the map could expand further. In 2025, WHO said the Americas reported the highest number of cases, while major transmission was also reported in French overseas departments in the Indian Ocean.

Recent history

On this site, chikungunya has 18 archived WHO notices or major pandemic records since 1996, which shows repeated reappearance rather than a one-off event. The archive includes major signals such as La Réunion in 2006, spread in India in 2006, the first recognized local transmission in Saint Martin in 2013, broad spread across the Americas from 2013 onward, and later outbreaks or local transmission in France, Italy, Kenya, Sudan, Congo, Chad, and others. WHO’s most recent global item, dated 2025-10-03, described a resurgence in 2025 with 445271 suspected and confirmed cases and 155 deaths reported from 40 countries between 2025-01-01 and 2025-09-30. Another WHO item, dated 2025-05-12, reported widespread transmission in La Réunion and increasing local transmission in Mayotte, the first in Mayotte since 2005 to 2006. Your site’s current records also note outbreaks in Nicaragua and France.

What to watch

The main warning signs are about spread, not just case counts. First, watch for new areas with local mosquito-borne transmission, especially places that already have Aedes aegypti or Aedes albopictus but little prior exposure. WHO says infected travelers can seed outbreaks in such settings. Second, watch for sustained transmission in Europe or other temperate regions during warm months, because that suggests the virus and vector are lining up well. Third, pay attention to severe disease in infants, older adults, and people with underlying illnesses, since these groups are more likely to have poor outcomes. Fourth, watch for surveillance gaps: WHO stresses that some outbreaks are recognized only late or retrospectively. Finally, vaccine supply and access would matter if vaccination becomes part of control policy, but the sources retrieved here do not clearly define current vaccine availability. Better mosquito surveillance, faster diagnosis, and prompt reporting are the clearest signals of preparedness.

Related outbreaks

Updated